Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | June 17, 2026 | June 18, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director · President and CEO | November 27, 2018 | November 30, 2018 |
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director | April 16, 2026 | April 20, 2026 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16 | Direct | 75,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 75,000 · Balance 75,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
GILEAD SCIENCES, INC.
Report date November 27, 2018 · Filed November 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,574,306 |
Reported balance
After 2018-11-27 transaction · row 1
1 source rowRow 1 · 2018-11-27 · Exercise / conversion · Acquired 280,000 · Balance 1,574,306 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.60 · Expires 2019-01-21 | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-27 · Exercise / conversion · Disposed 280,000 · Balance 0 F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 223,492 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 223,492 · Balance 223,492 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 24, 2009 Filed Dec 29, 2009 01:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 8,016 | $3.70 | $29,653.59 |
DisclosureSEC source: 0001179110-09-017495 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2009 Filed Dec 3, 2009 20:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-09-016226 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120 Underlying: Common Stock · 60,000 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 30, 2003 the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 30, 2007. Read SEC document |
| December 01, 2009 Filed Dec 3, 2009 20:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 60,000 | $46.03 | $2,761,542.00 |
DisclosureSEC source: 0001179110-09-016226 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,354 F1 · price: Sale prices reported here range from $45.79 to $46.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 01, 2009 Filed Dec 3, 2009 20:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 60,000 | $8.22 | $493,128.00 |
DisclosureSEC source: 0001179110-09-016226 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2009 Filed Sep 3, 2009 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-09-012901 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120 Underlying: Common Stock · 60,000 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 30, 2003 the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 30, 2007. Read SEC document |
| September 01, 2009 Filed Sep 3, 2009 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 60,000 | $45.46 | $2,727,672.00 |
DisclosureSEC source: 0001179110-09-012901 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,354 F1 · price: Sale prices reported here range from $44.68 to $45.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 01, 2009 Filed Sep 3, 2009 22:59 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 60,000 | $8.22 | $493,128.00 |
DisclosureSEC source: 0001179110-09-012901 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Amount of securities beneficially owned includes 479 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 30, 2009. Read SEC document |
| June 01, 2009 Filed Jun 3, 2009 20:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to Buy) · Derivative | 30,880 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-09-009086 · edgar.xml · derivative · entry 6 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,120 Underlying: Common Stock · 30,880 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 30, 2003 the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 30, 2007. Read SEC document |
| June 01, 2009 Filed Jun 3, 2009 20:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to Buy) · Derivative | 29,120 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-09-009086 · edgar.xml · derivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,120 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 30, 2003 the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 30, 2007. Read SEC document |
| June 01, 2009 Filed Jun 3, 2009 20:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $43.63 | $87,260.00 |
DisclosureSEC source: 0001179110-09-009086 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,875 Read SEC document |
| June 01, 2009 Filed Jun 3, 2009 20:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 58,000 | $42.83 | $2,484,076.20 |
DisclosureSEC source: 0001179110-09-009086 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,875 F1 · price: Sale prices reported here range from $42.55 to $43.27. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 01, 2009 Filed Jun 3, 2009 20:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 30,880 | $8.22 | $253,796.54 |
DisclosureSEC source: 0001179110-09-009086 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2009 Filed Jun 3, 2009 20:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 29,120 | $8.22 | $239,331.46 |
DisclosureSEC source: 0001179110-09-009086 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2009 Filed May 8, 2009 21:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 87,300 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-09-007471 · edgar.xml · derivative · entry 6 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,300 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 29, 2004 the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 29, 2008. Read SEC document |
| May 07, 2009 Filed May 8, 2009 21:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 87,300 | $44.45 | $3,880,546.11 |
DisclosureSEC source: 0001179110-09-007471 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,875 F2 · price: Sale prices reported here range from $44.30 to $44.60. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 07, 2009 Filed May 8, 2009 21:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 87,300 | $8.94 | $780,680.25 |
DisclosureSEC source: 0001179110-09-007471 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2009 Filed May 8, 2009 21:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 102,248 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-09-007471 · edgar.xml · derivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,300 Underlying: Common Stock · 102,248 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 29, 2004 the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 29, 2008. Read SEC document |
| May 06, 2009 Filed May 8, 2009 21:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 102,248 | $44.09 | $4,508,042.75 |
DisclosureSEC source: 0001179110-09-007471 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,875 F1 · price: Sale prices reported here range from $44.00 to $44.58. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 06, 2009 Filed May 8, 2009 21:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 102,248 | $8.94 | $914,352.74 |
DisclosureSEC source: 0001179110-09-007471 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2009 Filed May 7, 2009 01:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 199,092 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001179110-09-007246 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,728 Underlying: Common Stock · 199,092 shares Expires 2013-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 29, 2004 the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 29, 2008. Read SEC document |
| May 05, 2009 Filed May 7, 2009 01:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 199,092 | $44.49 | $8,857,722.54 |
DisclosureSEC source: 0001179110-09-007246 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,875 F1 · price: Sale prices reported here range from $44.34 to $44.68. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 05, 2009 Filed May 7, 2009 01:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 199,092 | $8.94 | $1,780,380.21 |
DisclosureSEC source: 0001179110-09-007246 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,967 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2009 Filed Mar 16, 2009 22:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 6,406 | $44.04 | $282,120.24 |
DisclosureSEC source: 0001179110-09-005160 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,875 Read SEC document |
| March 12, 2009 Filed Mar 16, 2009 22:30 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-09-005160 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,281 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 12, 2009. Read SEC document |
| March 02, 2009 Filed Mar 4, 2009 00:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-09-004069 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,120 Underlying: Common Stock · 60,000 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested 20% on January 30, 2003, the first anniversary date of the grant. The balance vested quarterly thereafter, and was fully vested on January 30, 2007. Read SEC document |
| March 02, 2009 Filed Mar 4, 2009 00:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 60,000 | $44.42 | $2,665,014.00 |
DisclosureSEC source: 0001179110-09-004069 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,281 Read SEC document |
| March 02, 2009 Filed Mar 4, 2009 00:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 60,000 | $8.22 | $493,128.00 |
DisclosureSEC source: 0001179110-09-004069 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2009 Filed Jan 24, 2009 02:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 140,000 | $0.00 Strike: $47.20 | $0.00 |
DisclosureSEC source: 0001179110-09-001496 · edgar.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2019-01-21 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 21, 2010 the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 21, 2014. Read SEC document |
| December 19, 2008 Filed Dec 24, 2008 01:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,980 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001179110-08-021490 · edgar.xml · derivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,732 Underlying: Common Stock · 2,980 shares Expires 2010-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on November 8, 2001, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on November 8, 2005. Read SEC document |
| December 19, 2008 Filed Dec 24, 2008 01:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 17,020 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001179110-08-021490 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,020 shares Expires 2010-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on April 5, 2001, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on April 5, 2005. Read SEC document |
| December 19, 2008 Filed Dec 24, 2008 01:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,980 | $5.88 | $17,519.42 |
DisclosureSEC source: 0001179110-08-021490 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2008 Filed Dec 24, 2008 01:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 17,020 | $3.70 | $63,028.46 |
DisclosureSEC source: 0001179110-08-021490 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2008 Filed Dec 3, 2008 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-08-020344 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,120 Underlying: Common Stock · 60,000 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested 20% on January 30, 2003, the first anniversary date of the grant. The balance vested quarterly thereafter, and was fully vested on January 30, 2007. Read SEC document |
| December 01, 2008 Filed Dec 3, 2008 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 60,000 | $43.73 | $2,623,800.00 |
DisclosureSEC source: 0001179110-08-020344 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,489 Read SEC document |
| December 01, 2008 Filed Dec 3, 2008 22:32 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 60,000 | $8.22 | $493,128.00 |
DisclosureSEC source: 0001179110-08-020344 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following the reported transaction includes 792 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 30, 2008. Read SEC document |
| December 01, 2008 Filed Dec 24, 2008 01:25 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 60,000 | $43.73 | $2,623,800.00 |
DisclosureSEC source: 0001179110-08-021489 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,281 Read SEC document |
| December 01, 2008 Filed Dec 24, 2008 01:25 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 60,000 | $8.22 | $493,128.00 |
DisclosureSEC source: 0001179110-08-021489 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2008 Filed Sep 4, 2008 18:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-08-016399 · edgar.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,120 Underlying: Common Stock · 60,000 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested 20% on January 30, 2003, the first anniversary date of the grant. The balance vested quarterly thereafter, and was fully vested on January 30, 2007. Read SEC document |
| September 02, 2008 Filed Sep 4, 2008 18:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 60,000 | $51.69 | $3,101,400.00 |
DisclosureSEC source: 0001179110-08-016399 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,489 Read SEC document |
| September 02, 2008 Filed Sep 4, 2008 18:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 60,000 | $8.22 | $493,128.00 |
DisclosureSEC source: 0001179110-08-016399 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2008 Filed Jun 3, 2008 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 26,720 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001179110-08-011293 · edgar.xml · derivative · entry 8 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,120 Underlying: Common Stock · 26,720 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested 20% on January 30, 2003, the first anniversary date of grant. The balance vested 5% every three months thereafter and was fully vested as of January 30, 2007. Read SEC document |
| June 02, 2008 Filed Jun 3, 2008 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 33,280 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001179110-08-011293 · edgar.xml · derivative · entry 7 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,280 shares Expires 2011-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options vested 20% on October 25, 2002, the first anniversary date of grant. The balance vested 5% every three months thereafter and was fully vested as of October 25, 2006. Read SEC document |
| June 02, 2008 Filed Jun 3, 2008 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $54.83 | $10,966.00 |
DisclosureSEC source: 0001179110-08-011293 · edgar.xml · nonDerivative · entry 6 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,489 Read SEC document |
| June 02, 2008 Filed Jun 3, 2008 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 402 | $54.78 | $22,021.56 |
DisclosureSEC source: 0001179110-08-011293 · edgar.xml · nonDerivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,689 Read SEC document |
| June 02, 2008 Filed Jun 3, 2008 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 59,298 | $54.74 | $3,245,972.52 |
DisclosureSEC source: 0001179110-08-011293 · edgar.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,091 Read SEC document |
| June 02, 2008 Filed Jun 3, 2008 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $54.73 | $5,473.00 |
DisclosureSEC source: 0001179110-08-011293 · edgar.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,389 Read SEC document |
| June 02, 2008 Filed Jun 3, 2008 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 26,720 | $8.22 | $219,606.34 |
DisclosureSEC source: 0001179110-08-011293 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2008 Filed Jun 3, 2008 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 33,280 | $8.58 | $285,585.66 |
DisclosureSEC source: 0001179110-08-011293 · edgar.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2008 Filed May 9, 2008 19:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Options (right to buy) · Derivative | 40,000 | $0.00 Strike: $54.14 | $0.00 |
DisclosureSEC source: 0001179110-08-009218 · edgar.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2018-05-07 F1 · derivative.exercise_date: Options vest over a five year period with 20% vesting May 7, 2009, the first anniversary of the grant. The options will continue to vest in quarterly installments over the next four years, and will be fully vested on May 7, 2013. Read SEC document |
| March 17, 2008 Filed Mar 19, 2008 22:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 6,404 | $47.55 | $304,510.20 |
DisclosureSEC source: 0001179110-08-006303 · edgar.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,489 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.